Bull Run
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsFinancial Statements

Sat Kartar Stock Price Today (NSE: SATKARTAR)

Sat Kartar

SATKARTARPharmaceuticals
₹132.10+₹0.00 (+0.00%)
Market Closed

Fundamental Score

...

Sat Kartar Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sat Kartar share price today is ₹132.10, up +0.00% on NSE/BSE as of 1 August 2026. Sat Kartar (SATKARTAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹208.66 (Cr). The 52-week high for SATKARTAR share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 12.09x, SATKARTAR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 28.97% and a debt-to-equity ratio of 0.04.

Sat Kartar Share Price Chart — NSE/BSE Historical Performance

No data
High
₹132.10
Low
₹132.10
Volume
0
Change
+0.00%

Sat Kartar share price chart: 0.00% return over the past month. 52-week high ₹N/A, 52-week low ₹N/A.

AI Research Briefing

Powered by Gemini · 2026-08-01

An SME micro-cap flashing massive paper profits but zero free cash flow, while institutions head for the exits.

Research Confidence
8.0/10High
MICRO-CAP DARK HORSESevere breakdown — down 17.02% in 1M and 29.26% in 3M.Cheap on paper at 12.09x P/E vs 34.89x industry, but reflects deep earnings quality skepticism.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Sat Kartar Life secured NSE trading approval on July 7, 2026, for 50,400 preferential shares allotted to non-promoters (locked until Jan 2027). The company reported a 74.31% surge in FY26 PAT to ₹17.10 Cr and laid out an aggressive ₹500 Cr revenue target by FY28. In April 2026, they acquired 100% of Plantomed Neutraceuticals for a ₹1.21 Cr cash consideration to aggressively expand into Ayurveda and wellness.

CORE STORY (THE REAL GAME)

This is an Ayurveda and wellness pivot masking an SME micro-cap structural risk. The street is struggling to digest the transition from a generic player to a holistic healthcare operator following the Plantomed acquisition and NABH accreditation for its Delhi hospital. The narrative is built on aggressive hyper-growth, but execution remains the sole determinant of survival.

Why Now
  • Preferential allotment of 50,400 shares approved for trading
  • FY26 PAT surged 74% to ₹17.10 Cr with a ₹500 Cr revenue target
  • Acquired Plantomed Neutraceuticals for ₹1.21 Cr
Potential Catalysts
  • Quarterly cash flow generation turning positive
  • Updates on the ₹500 Cr FY28 revenue execution
  • US generic tariff developments impacting broad sector sentiment
Key Risks
  • Zero Free Cash Flow over 5 years despite 37.42% ROCE
  • Severe liquidity risk typical of SME micro-caps
  • DIIs dumped 0.84% and FIIs dumped 0.31% recently
Institutional Activity

DIIs and FIIs are bailing, with DII holding down 0.84% and FII holding down 0.31%.

Macro Context

Broad pharma sentiment threatened by a proposed 200% US generic drug tariff, overshadowing domestic Ayurveda push.

Order Book / Expansion

Acquired Plantomed Neutraceuticals for ₹1.21 Cr cash to expand into Ayurveda and wellness.

Cash Flow Quality

Horrible — zero FCF generated over 5 years despite strong reported accounting profits.

3–6 Month Outlook

Dead money until paper profits translate into actual free cash flow. Expect continued downside drift.

Primary Thesis Risk

Earnings are an accounting illusion if they never convert to free cash flow.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

28.97%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

37.42%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

9.22%

Average operating profit margin over 5 years

Dividend Yield

0.53%

Annual dividend as % of current share price

Sat Kartar Valuation Check

Excellent

Price to Earnings (P/E)

12.09x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

63.62%

% shares held by company founders/management

Poor

FII Holding

0.13%

% shares held by foreign institutional investors

Poor

DII Holding

2.26%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

58.10%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

21.07%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.04x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

46.76x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sat Kartar Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SATKARTAR across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (28.97%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (37.42%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 12.09 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (58.10%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (21.07%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.04)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (46.76x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (63.62%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 2.39%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Sat Kartar vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Sat Kartar with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
Sat Kartar...✓
SATKARTAR •
54.9/100
₹132
₹208.66
12.1
Average
28.97%
Excellent
37.42%
Excellent
0.0
Excellent
—
—
0.53%
Sun Pharmaceuti...
SUNPHARMA • 524715
66.4/100
₹1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
Divis Laborator...
DIVISLAB • 532488
56.3/100
₹8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
Torrent Pharmac...
TORNTPHARM • 500420
51.4/100
₹5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA • 500087
40.2/100
₹1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
Zydus Lifescien...
ZYDUSLIFE • 532321
74.1/100
₹1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN • 500257
83.4/100
₹2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
Mankind Pharma ...
MANKIND • 543904
61.5/100
₹2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
Dr Reddys Labor...
DRREDDY • 500124
41/100
₹1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
Aurobindo Pharm...
AUROPHARMA • 524804
24.6/100
₹1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
Laurus Labs Ltd...
LAURUSLABS • 540222
34.1/100
₹1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Top Pharmaceuticals Stocks

View all →

Sat Kartar Quarterly Performance

Latest quarterly metrics for SATKARTAR — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

21.07%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

58.10%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Sat Kartar Financial Statements

Annual income statement, balance sheet and cash flow for Sat Kartar (SATKARTAR) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Sat Kartar

About SATKARTAR (Sat Kartar)

Sat Kartar (SATKARTAR) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ma...rket capitalisation of ₹208.66 (Cr). Sat Kartar has delivered a Return on Equity (ROE) of 28.97% and a ROCE of 37.42%. The debt-to-equity ratio stands at 0.04, reflecting the company's capital structure. Investors tracking SATKARTAR share price can monitor key metrics including P/E ratio, promoter holding of 63.62%, and quarterly earnings growth.

Company Details

Symbol:SATKARTAR
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

SATKARTAR Share Price: Frequently Asked Questions

What is the current share price of Sat Kartar?

Sat Kartar (SATKARTAR) trades at ₹132.10 on NSE. Market cap ₹208.66 (Cr). Educational data only.

What is the P/E ratio of Sat Kartar?

Sat Kartar has a P/E of 12.09x vs industry average 34.89x.

What is the Bull Run score for Sat Kartar?

Sat Kartar has a Bull Run score of 54.9/100 based on 25+ financial parameters.

Does Sat Kartar pay dividends?

Sat Kartar has a dividend yield of 0.53%. Past dividends don't guarantee future payments.

What is the ROE of Sat Kartar?

Sat Kartar has ROE of 28.97%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Sat Kartar?

Sat Kartar has debt-to-equity of 0.04.

Is Sat Kartar a good investment?

Bull Run gives Sat Kartar a score of 54.9/100. This is not investment advice — consult a SEBI-registered advisor.